[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5057 Introduced in House (IH)]

<DOC>






116th CONGRESS
  1st Session
                                H. R. 5057

  To clarify the treatment of pass-through status under the Medicare 
              outpatient payment system for certain drugs.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           November 12, 2019

Mr. Tonko (for himself and Mr. McKinley) introduced the following bill; 
  which was referred to the Committee on Energy and Commerce, and in 
    addition to the Committee on Ways and Means, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
  of such provisions as fall within the jurisdiction of the committee 
                               concerned

_______________________________________________________________________

                                 A BILL


 
  To clarify the treatment of pass-through status under the Medicare 
              outpatient payment system for certain drugs.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Pass-Through Technical Corrections 
Act''.

SEC. 2. CLARIFICATION OF PASS-THROUGH STATUS UNDER MEDICARE OPPS FOR 
              CERTAIN DRUGS.

    Notwithstanding section 1301 of the Consolidated Appropriations Act 
of 2018 (Public Law 115-141), in the case of a radiopharmaceutical drug 
for which pass-through status was provided pursuant to section 
1833(t)(6) of the Social Security Act (42 U.S.C. 1395l(t)(6)) and whose 
period of pass-through status initially expired on either December 31, 
2017, or December 31, 2018, if such radiopharmaceutical drug is 
indicated for positron emission tomography beta amyloid imaging covered 
under a coverage evidence development determination under section 
1862(a)(1)(E) of the Social Security Act (42 U.S.C. 1395y(a)(1)(E)), 
then such pass-through status shall be extended until such date that 
the coverage with evidence development review is determined by the 
Centers for Medicare & Medicaid Services to be completed.
                                 <all>